Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5885776 | 0.91 | KDM1A (0.39) | ARACACBKDM1ACCR5KCNH2 | |
| SCHEMBL5885627 | 0.90 | PDK1 (0.40) | ARACACBKDM1ADPP7PTGES | |
| SCHEMBL5885722 | 0.90 | ELANE (0.41) | ARACACB | |
| SCHEMBL5885843 | 0.89 | ACACB (0.41) | ARACACBKDM1ACCR5KCNH2 | |
| SCHEMBL5885777 | 0.88 | ACACB (0.39) | ARACACBKDM1ACCR5KCNH2 | |
| SCHEMBL5885594 | 0.86 | ACACB (0.42) | ARACACB | |
| SCHEMBL5886050 | 0.86 | ACACB (0.45) | ARACACBDPP7CCKBR | |
| Hydrochloric Acid SCHEMBL5885611 | 0.85 | ACACB (0.41) | ARACACB | |
| SCHEMBL5885457 | 0.85 | MEN1 (0.43) | KDM1APTGESMEN1NPC1KMT2A | |
| SCHEMBL5885754 | 0.85 | ACACB (0.40) | ARACACBCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1404648-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003101942-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-11 | — | — | WO | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | AR 1214/4885ACACB 2639/4885KDM1A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.